A Phase 1, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AMG 133 in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
Latest Information Update: 02 Mar 2026
At a glance
- Drugs Maridebart cafraglutide (Primary)
- Indications Renal failure; Renal impairment
- Focus Pharmacokinetics
- Sponsors Amgen
Most Recent Events
- 02 Mar 2026 New trial record